Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue

Expert Review of Proteomics

Volumn 7, Issue 2, 2010, Pages 227-237

  Matsuda, Kant M ^a   Chung, Joon Yong ^a   Hewitt, Stephen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Formalin fixed paraffin embedded tissue; High throughput; Multiplex protein analysis; Protein array; Protein extraction; Proteomic profiling; Radiographic histopathologic correlation; Tissue immunoblotting; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; PROTEIN; TRASTUZUMAB;

HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE SECTION;

ANIMALS; FORMALDEHYDE; HUMANS; IMMUNOBLOTTING; PARAFFIN EMBEDDING; PROTEOMICS; TISSUE FIXATION;

EID: 77950817999     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.106     Document Type: Review

References (78)

1. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 368-371 (1995).
2. McCarthy JE. Posttranscriptional control of gene expression in yeast. Microbiol. Mol. Biol. Rev. 62(4), 1492-1553 (1998). (Pubitemid 28558306)
3. Parekh RB, Rohlff C. Post-translational modification of proteins and the discovery of new medicine. Curr. Opin. Biotechnol. 8(6), 718-723 (1997). (Pubitemid 27517249)
4. Marcotte EM. Measuring the dynamics of the proteome. Genome Res. 11(2), 191-193 (2001).
5. Hewitt SM. The application of tissue microarrays in the validation of microarray results. Methods Enzymol. 410, 400-415 (2006). (Pubitemid 44287017)
6. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4(7), 844-847 (1998). (Pubitemid 28331029)
7. Hewitt S, Lewis FA, Cao Y et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch. Pathol. Lab. Med. 132(12), 1929-1935 (2008).
8. Takikita M, Chung JY, Hewitt SM. Tissue microarrays enabling high-throughput molecular pathology. Curr. Opin. Biotechnol. 18(4), 318-325 (2007). (Pubitemid 47393621)
9. Hewitt S, Takikta M, Abedi-Ardekani et al. Validation of proteomics based discovery with tissue microarrays. Proteomics Clin. Appl. 2, 1460-1466 (2008).
10. Arteaga CL, Khuri F, Krystal G et al. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin. Onco. 29(1), 15-26 (2002). (Pubitemid 34226515)
11. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin. Oncol. 28(5), 67-79 (2001). (Pubitemid 33065112)
12. Herbst RS, Hidalgo M, Pierson AS et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. 29(1), 66-77 (2002). (Pubitemid 34226521)
13. Arteaga CL, Khuri F, Krystal G et al. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5), 1593-1611 (2002).
14. Fountaine T, Wincovitch SM, Geho DH et al. Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod. Pathol. 19(9), 1181-1191 (2006). (Pubitemid 44268188)
15. Chung JY, Lee SJ, Ylaya K et al. A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. Proteomics Clin. Appl. 2, 1539-1547 (2008).
16. Mangé A, Chaurand P, Perrochia H et al. Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery. J. Proteome Res. 8(12), 5619-5628 (2009).
17. Fernandez D, Bhargava R, Hewitt SM et al. Infrared spectroscopic imaging for histopathologic recognition. Nat. Biotechnol. 23(4), 469-474 (2005). (Pubitemid 41724923)
18. Chung J, Braunschweig T, Hu N et al. A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 15(7), 1403-1408 (2006). (Pubitemid 44125301)
19. Mason J, O'Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J. Histochem. Cytochem. 39(2), 225-229 (1991).
20. Ikeda K, Monden T, Kanoh T et al. Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J. Histochem. Cytochem. 46, 397-403 (1998). (Pubitemid 28117390)
21. Chu WS, Liang Q, Liu J et al. A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section. Lab. Invest. 85, 1416-1428 (2005). (Pubitemid 41509389)
22. Prieto DA, Hood BL, Darfler MM et al. Liquid tissue TM: proteomic profiling of formalin-fixed tissues. Biotechniques 38, S32-S35 (2005).
23. Yamashita S, Okada Y. Mechanisms of heat-induced antigen retrieval: analysis in vitro employing SDS-PAGE and immunohistochemistry. J. Histochem. Cytochem. 53, 13-21 (2005). (Pubitemid 40130116)
24. Shi SR, Liu C, Balgley BM et al. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J. Histochem. Cytochem. 54, 739-743 (2006). (Pubitemid 43736896)
25. Addis MF, Tanca A, Pagnozzi D et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics 9, 3815-3823 (2009).
26. Becker KF, Schott C, Hipp S et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211, 370-378 (2007). (Pubitemid 46172713)
27. Hultschig C, Kreutzberger J, Seitz H et al. Recent advances of protein microarrays. Curr. Opin. Chem. Biol. 10, 4-10 (2006). (Pubitemid 43202281)
28. Lueking A, Cahill DJ, Müllner S. Protein biochips: a new and versatile platform technology for molecular medicine. Drug Discov. Today 10, 789-794 (2005). (Pubitemid 40744923)
29. Wingren C, Borrebaeck CA. Antibody microarray analysis of directly labeled complex proteomes. Curr. Opin. Chem. Biol. 19, 55-61 (2008).
30. Braunschweig T, Kaserer K, Chung J-Y et al. Proteomic expression profiling of thyroid neoplasms with antibody arrays. Proteomics Clin. Appl. 1, 264-271 (2007).
31. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16), 1981-1989 (2001). (Pubitemid 32458030)
32. Grubb RL, Calvert VS, Wulkuhle JD et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3, 2142-2146 (2003).
33. Geho D, Lahar N, Gurnani P et al. Pegylated, streptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug. Chem. 16, 559-566 (2005). (Pubitemid 40696047)
34. Janzi M, Odling J, Pan-Hammarstorm Q et al. Serum microarrays for large scale screening of protein levels. Mol. Cell Proteomics 4, 1942-1947 (2005). (Pubitemid 41830188)
35. Jiang R, Mircean C, Shmulevich I et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6, 2964-2971 (2006). (Pubitemid 43806395)
36. Weissenstein U, Schneider MJ, Pawlak M et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in the tissue extracts. Proteomics 6, 1427-1436 (2006).
37. Sheehan KM, Calvert VS, Kay EW et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell Proteomics 4, 346-355 (2005).
38. Pirnia F, Pawlak M, Thallinger GG et al. Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: expression of apoptosis-related proteins in human colon cancer. Proteomics 9, 3535-3548 (2009).
39. Gulmann C, Sheehan KM, Conroy RM et al. Quantitative cell signaling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J. Pathol. 218, 514-519 (2009).
40. He M, Stoevesandt O, Palmer EA et al. Printing protein arrays from DNA arrays. Nat. Methods 5(2), 175-177 (2008). (Pubitemid 351181746)
41. Caldwell R, Caprioli RM. Tissue profiling by mass spectrometry: a review of methodology and applications. Mol. Cell Proteomics 4(4), 394-401 (2005). (Pubitemid 40590559)
42. Caprioli R, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 69(23), 4751-4760 (1997). (Pubitemid 127485123)
43. Stoeckli M, Chaurand P, Hallahan DE et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7(4), 493-496 (2001). (Pubitemid 32298555)
44. Suzuki K, Yu X, Chaurand P et al. Epididymis-specific promoter-driven gene targeting: a transcription factor which regulates epididymis-specific gene expression. Mol. Cell Endocrinol. 250(1-2), 184-189 (2006).
45. Chaurand P, Fouchécourt S, DaGue BB et al. Profiling and imaging proteins in the mouse epididymis by imaging mass spectrometry. Proteomics 3(11), 2221-2239 (2003). (Pubitemid 37414087)
46. Khatib-Shahidi S, Andersson M, Herman JL et al. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal. Chem. 78(18), 6448-6456 (2006). (Pubitemid 44418954)
47. Hsieh Y, Casale R, Fukuda E et al. Matrix-assisted laser desorption/ ionization imaging mass spectrometry for direct measurement of clozapine in rat brain tissue. Rapid Commun. Mass Spectrom. 20(6), 965-972 (2006).
48. Ronci M, Bonanno E, Colantoni A et al. Protein unlocking procedures of formalin-fixed paraffin-embedded tissues: application to MALDI-TOF imaging MS investigations. Proteomics 8(18), 3702-3714 (2008).
49. Chen T, Lee MJ, Kim YS et al. Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation. Anal. Chem. 80(16), 6390-6396 (2008).
50. Chung J, Braunschweig T, Baibakov G et al. Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics 6(3), 767-774 (2006). (Pubitemid 43260202)
51. Chung JY, Hong SM, Choi BY et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin. Cancer Res. 15(2), 660-667 (2009).
52. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 19(2), 205-216 (2008).
53. Comerford K, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1a-dependent P-glycoprotein expression in hypoxia. Cancer Res. 64(24), 9057-9061 (2004). (Pubitemid 39665517)
54. Koshiji M, Kageyama Y, Pete PE et al. HIF-1a induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23(9), 1949-1956 (2004). (Pubitemid 38902073)
55. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12(2), 108-113 (2007).
56. Fels DR, Koumenis C. HIF-1a and p53: the ODD couple? Trends Biochem. Sci. 30(8), 426-429 (2005).
57. Comerford K, Wallace TJ, Karhausen J et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12), 3387-3394 (2002). (Pubitemid 34651384)
58. Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br. J. Cancer 95(1), 1-5 (2006).
59. Manalo DJ, Rowan A, Lavoie T et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105(2), 659-669 (2005). (Pubitemid 40070750)
60. Calvani M, Trisciuoglio D, Bergamaschi C et al. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 68(1), 285-291 (2008). (Pubitemid 351380130)
61. Willmann JK, van Bruggen N, Dinkelborg LM et al. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7(7), 591-607 (2008).
62. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 3(3), 137-144 (2002).
63. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005). (Pubitemid 41464705)
64. Cheng Z, De Jesus OP, Namavari M et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J. Nucl. Med. 49(5), 804-813 (2008). (Pubitemid 351717547)
65. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 42(7), 832-841 (2009).
66. Ren G, Zhang R, Liu Z et al. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J. Nucl. Med. 50(9), 1492-1499 (2009).
67. Ménard S, Balsari A, Tagliabue E et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann. Oncol. 19(10), 1706-1712 (2008).
68. Robitaille P, Abduljalil AM, Kangarlu A. Ultra high resolution imaging of the human head at 8 tesla: 2K × 2K for Y2K. J. Comput. Assist. Tomogr. 24(1), 2-8 (2000).
69. Li TQ, van Gelderen P, Merkle H et al. Extensive heterogeneity in white matter intensity in high-resolution T2*- weighted MRI of the human brain at 7.0 T. Neuroimage 32(3), 1032-1040 (2006). (Pubitemid 44308284)
70. Woods RP, Grafton ST, Watson JD et al. Automated image registration: II. Intersubject validation of linear and nonlinear models. J. Comput. Assist. Tomogr. 22(1), 153-165 (1998).
71. Li X, Link JM, Stekhova S et al. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug. Chem. 19(8), 1684-1688 (2008).
72. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 6, 135-143 (2006).
73. Valonen PK, Lehtimaki KK, Vaisanen TH et al. Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: correlation with cell density. J. Magn. Reson. Imag. 19, 389-396. (2004).
74. Moseley ME, Cohen Y, Kucharczyk J et al. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 176(2), 439-445 (1990). (Pubitemid 20225133)
75. Hacke W, Warach S. Diffusion-weighted MRI as an evolving standard of care in acute stroke. Neurology 54(8), 1548-1549 (2000). (Pubitemid 30226791)
76. Zhao M, Pipe JG, Bonnett J et al. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br. J. Cancer 73(1), 61-64 (1996). (Pubitemid 126422064)
77. Chenevert TL, Stegman LD, Taylor JM et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl Cancer Inst. 92(24), 2029-2036 (2000).
78. Mardor Y, Roth Y, Lidar Z et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61(13), 4971-4973 (2001). (Pubitemid 32681520)